Eli Lilly and Company (NYSE:LLY) Shares Sold by Bank of New Hampshire

Bank of New Hampshire lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 42.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 709 shares of the company’s stock after selling 528 shares during the period. Bank of New Hampshire’s holdings in Eli Lilly and Company were worth $413,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of LLY. Nadler Financial Group Inc. lifted its holdings in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Nadler Financial Group Inc. now owns 2,427 shares of the company’s stock valued at $1,415,000 after purchasing an additional 65 shares in the last quarter. Bailard Inc. raised its holdings in shares of Eli Lilly and Company by 4.6% during the fourth quarter. Bailard Inc. now owns 12,987 shares of the company’s stock worth $7,570,000 after acquiring an additional 576 shares in the last quarter. BIP Wealth LLC raised its holdings in shares of Eli Lilly and Company by 45.5% during the fourth quarter. BIP Wealth LLC now owns 896 shares of the company’s stock worth $522,000 after acquiring an additional 280 shares in the last quarter. Sycomore Asset Management raised its holdings in shares of Eli Lilly and Company by 446.7% during the fourth quarter. Sycomore Asset Management now owns 4,237 shares of the company’s stock worth $2,464,000 after acquiring an additional 3,462 shares in the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 1.2% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 47,809 shares of the company’s stock worth $27,869,000 after acquiring an additional 568 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of Eli Lilly and Company stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on LLY shares. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Morgan Stanley increased their price objective on Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Finally, Truist Financial reissued a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Price Performance

LLY traded down $7.33 during midday trading on Thursday, reaching $724.87. 2,598,050 shares of the company’s stock were exchanged, compared to its average volume of 3,033,787. The firm has a market capitalization of $688.74 billion, a price-to-earnings ratio of 124.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The business has a 50-day simple moving average of $763.40 and a two-hundred day simple moving average of $664.52.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 earnings per share. Eli Lilly and Company’s quarterly revenue was up 28.1% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 12.52 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.